Reglutide 1.34 mg/ml is a glucagon-like peptide-1 (GLP-1) receptor agonist designed to help adults with type 2 diabetes mellitus manage blood glucose levels effectively. It acts as an adjunct to diet and exercise to improve glycemic control and also reduces the risk of major adverse cardiovascular events in patients with established cardiovascular disease. In addition to glycemic management, Reglutide is indicated for chronic weight management in adults with obesity or overweight and at least one weight-related comorbidity, such as hypertension, dyslipidemia, or type 2 diabetes.

Reglutide mimics the action of natural GLP-1, a hormone that regulates blood glucose by stimulating insulin secretion and inhibiting glucagon release in a glucose-dependent manner. It also delays gastric emptying slightly, contributing to improved postprandial glucose control and weight reduction. Its long-acting formulation allows for convenient once-weekly subcutaneous injections.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Therapeutic Class

GLP-1 receptor agonist

Pharmacology and Mode of Action

Reglutide 1.34 mg/ml is a GLP-1 analogue with 94% sequence homology to human GLP-1. It binds selectively to GLP-1 receptors and activates glucose-dependent mechanisms to lower blood sugar. Albumin binding prolongs its half-life by reducing renal clearance and protecting it from metabolic degradation. Additionally, it is stabilized against DPP-4 enzyme degradation, allowing for sustained activity.

Mechanisms of action include:

• Stimulating insulin secretion when blood glucose is elevated

• Suppressing glucagon secretion in a glucose-dependent manner

• Slightly delaying gastric emptying to improve post-meal glucose levels

Indications

Reglutide 1.34 mg/ml is indicated for:

• Adjunct therapy to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus

• Reducing the risk of major adverse cardiovascular events in adults with type 2 diabetes and established cardiovascular disease

• Chronic weight management in adults with:

  • BMI ≥ 30 kg/m² (obesity)

  • BMI ≥ 27 kg/m² (overweight) with at least one weight-related comorbidity (e.g., hypertension, type 2 diabetes, dyslipidemia)

Dosage and Administration

Subcutaneous injection (once weekly):

• Start: 0.25 mg once weekly for 4 weeks

• Dose escalation every 4 weeks: 0.5 mg → 1 mg → 1.7 mg → maintenance 2.4 mg weekly

• If a dose is not tolerated, escalation may be delayed or temporarily reduced to 1.7 mg weekly

• Inject in the abdomen, thigh, or upper arm at any time of day, with or without meals

Oral tablet (daily, if applicable):

• Start with 3 mg once daily for 30 days

• Increase to 7 mg daily; may escalate to 14 mg if additional glycemic control is needed

• Take at least 30 minutes before the first meal or other oral medications with no more than 4 ounces of plain water

  রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Contraindications

• Personal or family history of medullary thyroid carcinoma (MTC)

• Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)

• Known hypersensitivity to Reglutide

Side Effects

• Gastrointestinal: nausea, vomiting, diarrhea

• Risk of pancreatitis; monitor for severe persistent abdominal pain

• Possible thyroid C-cell tumors (unknown in humans)

• Hypoglycemia when used with insulin or sulfonylureas

• Acute kidney injury in rare cases

Precautions and Warnings

• Monitor for signs of pancreatitis

• Patients with diabetic retinopathy should be observed for progression

• Never share pens between patients

• Use with caution in patients with renal or hepatic impairment

Pregnancy and Lactation

Use only if the potential benefit outweighs the risk. Discontinue at least 2 months before planned pregnancy due to long washout. Safety in breastfeeding is unknown.

Storage Conditions

• Store in a refrigerator at 2°C–8°C

• After first use, keep pen for up to 56 days in the refrigerator

• Protect from light, do not freeze, and keep pen capped when not in use.